Number 795 • April 2019

Product supply shortages addressed for Alberta Drug Benefit List (ADBL)

Alberta Blue Cross has been advised by Sivem Pharmaceuticals ULC that the shortage for Telmisartan HCTZ 80 mg/12.5 mg Tablet (DIN 02390302) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 22, 2019**.

TELMISARTAN/ HYDROCHLOROTHIAZIDE

80 MG / 12.5 MG TABLET

00002419114	ACH-TELMISARTAN HCTZ	AHI	\$ 0.2098
00002456389	AURO-TELMISARTAN HCTZ	AUR	\$ 0.2098
00002393557	SANDOZ TELMISARTAN HCT	SDZ	\$ 0.2098
00002390302	TELMISARTAN HCTZ	SIV	\$ 0.2098
00002395355	TELMISARTAN/HCTZ	SNS	\$ 0.2098
00002330288	TEVA-TELMISARTAN HCTZ	TEV	\$ 0.2098
00002244344	MICARDIS PLUS	BOE	\$ 1.2474

Alberta Blue Cross has been advised by Aspen Pharmacare Canada Inc. that the shortage for Arixtra 7.5 mg/0.6 ml Injection Syringe (DIN 02258056) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 22, 2019**.

FONDAPARINUX SODIUM

7.5 MG / SYR INJECTION SYRINGE

00002258056	ARIXTRA (0.6 ML SYRINGE)	APC	\$ 17.5000
00002406896	FONDAPARINUX SODIUM (0.6 ML SYRINGE)	DRL	\$ 18.1356

Alberta Blue Cross has been advised by Teva Canada Limited that the shortage for Teva-Naratriptan 1 mg Tablet (DIN 02314290) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 25, 2019**.

NARATRIPTAN HCL

1 MG TABLET

00002314290	TEVA-NARATRIPTAN	TEV	\$ 11.9041
00002237820	AMERGE	GSK	\$ 14.7667

Alberta Blue Cross has been advised by AA Pharma Inc that the shortage for Lorazepam 2 mg Sublingual Tablet (DIN 02410761) has been resolved. Due to the long-term nature of this shortage, a transition period will be applied, and as a result, the LCA price policy will be reapplied to the following grouping effective **April 29, 2019**.

LORAZEPAM

2 MG SUBLINGUAL TABLET

00002410761	LORAZEPAM	AAP	\$ 0.1711
00002041472	ATIVAN	PFI	\$ 0.2328

When you have questions:

For assistance with benefit or claim inquiries, please contact an Alberta Blue Cross Pharmacy Services Provider Relations contact centre representative at:

780-498-8370 (Edmonton and area) • **403-294-4041** (Calgary and area) • **1-800-361-9632** (toll free) **FAX 780-498-8406** (Edmonton and area) • **FAX 1-877-305-9911** (toll free)

Alberta Blue Cross offers online access to current Pharmacy Benefacts and supplemental claiming information to assist with the submission of your direct bill drug claims. **Visit** ab.bluecross.ca/providers/pharmacy-home.php



